Starpharma (ASX:SPL) launches VivaGel in Europe

Company News

by Rachael Jones

Starpharma (ASX:SPL) today announced that VivaGel BV has been launched in Central and Eastern European region. 

This launch follows European launches in Germany, UK and several other European countries. 

VivaGel BV is available Over-The-Counter in the region, without the need to see a doctor or obtain a prescription.

The region gives access to more than 45 million women and Mundipharma continues to rollout the product in the region.

VivaGel BV is a novel, non-antibiotic therapy for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV.

Shares in Starpharma (ASX:SPL) are trading 6.7 per cent higher at $1.03.

Rachael Jones

Finance News Network
Rachael comes to FNN after working for Fairfax Media covering international breaking news, including the global economy and politics. She joined FNN in February 2018. She has reported on Australia’s finance news for various organisations since 2000 and has also interviewed a number of key business players, including Bill Gates. Rachael has also worked across a number of countries, including the UK and the US.